People

Debbie Ledet leads market access at Octave Bioscience. Her diagnostics and reimbursement experience includes NeoGenomics, Perspectum, Biotheranostics, Natera and Johnson & Johnson.

Marcel Konrad is Octave Bioscience’s CFO. His earlier finance leadership roles include Medexus Pharmaceuticals, CareDx, Santen and Novartis. He is a US CPA.

Doug Biehn is president and CEO of Octave Bioscience and a board director. His previous healthcare leadership roles include Cala Health, iRhythm, McKesson, AliveCor and Blue Shield of California.

Jake Yount is a managing principal at Echo Health Advisors. He previously worked at Blue Cross NC in finance, product development, provider payment and healthcare operations. He holds an East Carolina MBA.

David Weir is an executive assistant with Echo Health Advisors, based in Seattle. He also serves as board secretary for Portland’s Triangle Productions theatre company.

Annika Van Gilder is a senior associate at Echo Health Advisors. Her earlier work includes Arc Health, global health research funding and behavioral health initiatives. She holds a Michigan Ross MBA.

Ralph Sabin is a senior advisor to Echo’s strategic investment team. He co-founded Pacific Venture Group and previously held senior positions at Ernst & Young and Fortis Advisors.

Stephanie Leonard is an executive assistant at Echo Health Ventures, based in Seattle. She is also involved in the Pacific Northwest art and film community.

Amanda Johnson is a senior analyst in Echo’s legal and administration team. She previously worked in administration at a biotechnology company and as a corporate paralegal at Wyrick Robbins.

Jose Guerola is a principal in Echo’s strategic investment team. He previously invested at Johnson & Johnson’s investment arm and Carlyle and worked in Credit Suisse M&A. He holds a Wharton MBA.

David Goad is a senior associate in Echo’s strategic investment team. His earlier experience includes Cambia finance and corporate development in life sciences and education. He holds a Washington State MBA.

Dustin Duke is Echo Health Ventures’ controller. He previously worked in public accounting at BDO and Grant Thornton, including audits of investment businesses and life-sciences funds. He holds a CPA licence.

Bob Dolan is a managing principal at Echo Health Advisors. His healthcare leadership background includes The Partnership for a Healthy Arkansas, Life & Specialty Ventures and Saint Francis Heart Hospital.

Nash Carey-Ewend is a senior associate at Echo Health Advisors. He previously worked in business development and client relations at 3D-printing company Carbon and in technology deployment at UNC Health.

Misty Burgner directs operations and administration at Echo Health Ventures. She previously spent more than two decades at Blue Cross NC, including leadership in legal and administrative operations.

Taylor Auten is general counsel at Echo Health Ventures. He previously advised on investments and corporate transactions at Wyrick Robbins and Sullivan & Cromwell. He studied law at Duke and engineering at NC State.

Omair Ahmed is a principal in Echo’s strategic investment team and a current board observer at Scipher Medicine, Abacus Insights, Ideon and Vori Health. His earlier roles include Accenture Strategy, Merck’s investment fund and 7Wire Ventures.

Jessica A. Zeaske is a managing partner in Echo’s strategic investment team. She previously invested at GE Ventures and Lemhi Ventures. Her education includes Stanford, Johns Hopkins and Regis University.

Kurt Sheline is a strategic investment partner at Echo Health Ventures. His earlier roles include Cascade Asset Management, Cascadia Capital, Pathway Capital Management and Merrill Lynch. He holds a Berkeley MBA. Kurt Sheline is publicly listed by Thyme Care as Board Observer. The directory describes their outside affiliation as Partner, Echo Health Ventures; that title is context, not an executive position at Thyme Care.

Troy Arnold is a partner in Echo Health Advisors. He previously worked in strategy, provider partnerships and value-based care at Blue Cross NC. He holds business and healthcare administration degrees from UNC and Minnesota.

Suzanne McLemore leads Echo Health Advisors as a managing partner. She previously directed technology partnerships at Cambia and worked in strategy and partnerships at IBM. She holds degrees from Columbia and Duke.

Dusty Lieb leads investments at Echo Health Ventures. His background includes Cambia strategic investing and healthcare transactions at Harris Williams. He studied economics at the University of Pennsylvania.

Jon Eide is Echo Health Ventures’ managing partner and COO. He previously practised corporate law at Robinson Bradshaw and worked in banking and audit. He holds a Northwestern law degree and a CPA licence.

Rob Coppedge is CEO and a founder of Echo Health Ventures. He previously led Cambia Health Solutions’ diversified businesses and investment activities and was a partner at Capitol Health Partners.

Torsten Hombeck has served as Scipher Medicine’s interim chief financial officer since March 2026. His biotechnology finance career includes CFO roles at Akari Therapeutics, Aspira Women’s Health, Agennix and GPC Biotech, and executive positions at Promethera Biosciences and Cytonet. He holds an MBA and a doctorate in finance from EBS University of Business and Law in Germany.

aMoon general partner and Scipher Medicine board director. Previously invested at Signet Healthcare Partners and Joddes and researched pharmaceutical equities at Morgan Stanley and Goldman Sachs. Todd Sone is published by aMoon as General Partner. Healthcare investor with experience in equity research and institutional investing; co-leads the Growth strategy. Todd Sone is a current Iantrek board member and is identified by the company as aMoon general partner. The issuer2025SeriesC announcement names aMoon as joining the round, without formally assigning co-lead status.

Scipher Medicine scientific co-founder and board director. Harvard physician-scientist and physician-in-chief emeritus at Brigham and Women's Hospital, with expertise in cardiovascular biology and network medicine.

Scipher Medicine senior vice president for network medicine and data science. A physicist trained in the Barabasi laboratory, working on the Spectra platform, biomarker discovery and therapeutic target identification.

Scipher Medicine board director and biotechnology adviser with experience in investment banking, corporate finance, mergers and acquisitions.

Scipher Medicine chief business officer, as listed in its current leadership directory.

Scipher Medicine strategic partnership consultant with experience in cross-border licensing, alliances and technology transfer, including work at Ardelyx, Acucela and Peninsula Pharmaceuticals.

Scipher Medicine consultant for strategic partnerships and precision medicine. Previously worked in diagnostic product strategy and partnerships at QIAGEN, AstraZeneca, Quest, Paige.AI, Nuclea.AI and OMAPiX.

Scipher Medicine senior director of business development; named in the current public directory.

Scipher Medicine scientific co-founder and director. Network scientist at Northeastern University and Harvard Medical School researching complex systems and network medicine.

Scipher Medicine chief operating officer with experience in precision medicine, product development and clinical operations. Previously held leadership roles at Aspira, CareDx and Kaiser Permanente.

Scipher Medicine president, CEO and board director. Previously led CareDx and worked in strategy, partnerships and portfolio development at Ardelyx, AstraZeneca and other pharmaceutical companies; trained as a physician-scientist.

Blue Owl Healthcare Opportunities managing director and Scipher Medicine board director. Previously co-founded Cowen Healthcare Investments and worked in biotechnology investment banking.

Laurion Capital Management partner since 2017, also known as Jerry Zhou. Develops quantitative and quantitative-informed discretionary strategies and leads biotechnology investing. Holds a Tsinghua biological sciences degree and a Harvard doctorate in biochemistry and molecular pharmacology.

Laurion Capital Management co-founder and founding partner, sharing responsibility for capital allocation, strategy development and risk management. Previously worked in JPMorgan equity derivatives and proprietary trading; holds a Princeton computer science degree.

Laurion Capital Management co-founder and founding partner. Previously a JPMorgan managing director in equity derivatives, overseeing structured options and proprietary quantitative equity-arbitrage and volatility strategies. Holds a Harvard economics degree.

Delos Capital operations manager since 2022, based in Taipei. Previously worked in education and instruction; holds a degree from National Chung Hsing University and completed law extension courses at National Taiwan University.

Delos Capital executive assistant in Hong Kong since 2022. Previously worked in Nan Fung Group's corporate legal department and studied professional English communications at City University of Hong Kong.

Delos Capital financial controller since 2018, responsible for accounting, tax, reporting and compliance in Hong Kong. Previously worked in finance and corporate tax at Bank of America Merrill Lynch and at Ernst & Young; a certified accountant.

Delos Capital office manager since June 2024, supporting its Boston-area operations. Previously worked in finance and operations at a technology company; holds an international relations degree from Saint Anselm College.

Delos Capital Hong Kong office manager since 2015. Previously managed office and executive support at Permira and worked in Goldman Sachs Asia investment banking administration.

Delos Capital managing director since 2024. Previously invested at Leaps by Bayer, founded a genomic diagnostic company while at RA Capital and worked on transactions at Moderna. Also teaches bio-innovation; based in Cambridge.

Delos Capital associate since 2022. Previously researched drug targets and autoimmune disease at Boehringer Ingelheim; holds a genetics doctorate from Rochester and a biology degree from Xiamen University. Based in Hong Kong.

Delos Capital partner since 2024. Previously an operating partner at Flagship Pioneering, COO of Laronde and a Moderna executive overseeing clinical programs and manufacturing. Earlier worked at McKinsey and Merck; based in Cambridge.

Delos Capital founder and managing partner since 2014. Previously a partner and Asia co-head at Permira, a Goldman Sachs managing director and a corporate finance lawyer at Davis Polk. Also co-founded Curamir and Tulavi; based in Hong Kong.

UCSF pharmaceutical chemistry professor and TRexBio scientific founder, also known as James Wells. Researches protein engineering and molecular tools for inflammation and cancer; founded the UCSF Small Molecule Discovery Center and Sunesis Pharmaceuticals.

Oxford gastroenterologist and immunologist, and TRexBio scientific founder. Researches intestinal immune biology, inflammatory bowel disease and the cellular organization of inflamed tissue.

UCSF dermatologist, skin immunologist and TRexBio scientific co-founder. Studies immune regulation in tissues and development of therapies targeting regulatory T cells; also co-founded Sitryx and Delinia.

Johns Hopkins immunologist and TRexBio scientific founder. Directs cancer immunotherapy research focused on T-cell biology, cancer vaccines and immune regulation.

UCSF dermatologist and TRexBio scientific founder. Leads research on psoriasis and inflammatory skin disease, using genetics, functional genomics, tissue biobanks and single-cell profiling.

UCSF oncologist and TRexBio scientific founder focused on melanoma, immunotherapy and early clinical trials. Trained in medicine, internal medicine and hematology-oncology.

TRexBio scientific founder and physician-scientist with experience building biotechnology companies and investing in life sciences. Research interests include metabolic disease and novel therapeutic development.

SV Health Investors managing partner since January 2024, having joined in 2022. Previously a Pfizer Ventures partner through December 2021. TRexBio director since May 2019, with resignation planned before IPO registration effectiveness; trained in biochemistry and molecular biophysics.

SV Health Investors senior partner and TRexBio director, also known as Mike Ross. Previously founded and led Arris Pharmaceutical and MetaXen and worked in scientific leadership at Genentech.

Alexandria Real Estate Equities founder and executive chairman, and founder of Alexandria Venture Investments. TRexBio director since November 2024; has experience in life sciences real estate, venture investing and corporate finance. Current Alexandria primary affiliation: founder and continuing leader of Alexandria Venture Investments, a corporate venture platform established in 1996. He is the parent’s Executive Chairman and Founder; earlier Chairman, CEO and President tenure ended April 2018. His prior legal career focused on corporate finance, venture investments and mergers, with earlier CPA and tax work; he holds UCLA undergraduate and JD degrees. This institution-level affiliation does not imply a personal cash check.

Biotechnology entrepreneur and TRexBio director. Co-founded Plexxikon and previously served as its CEO; also founded Sugen and worked at Boehringer Mannheim. Trained in molecular genetics at Heidelberg.

Eli Lilly vice president and global head of Lilly Gateway Labs, and TRexBio director. Has held scientific and leadership roles in research and drug development; trained in membrane biophysics and drug transport. Julie Gilmore leads Lilly Gateway Labs and Catalyze360 portfolio management as vice president and global head. Her Lilly career spans research, scientific communications, European clinical operations and neurodegeneration/pain portfolio management. She trained in membrane biophysics at Purdue and drug transport at Indiana University.

Immunocore CFO and head of corporate development, and TRexBio director. Previously spent two decades at Eli Lilly in finance, investor relations, transactions and business development.

Polaris Partners partner focused on early-stage biotechnology and healthcare. Previously conducted research at Inzen Therapeutics and Vertex; holds a Harvard chemical biology doctorate. TRexBio director as of October 5, 2026, with resignation planned immediately before IPO registration effectiveness. BeMe’s2021issuer announcement names her among its board members and advisors. That collective description does not assign an individual director seat; recorded affiliation remains qualified and historical after acquisition. Polaris managing partner in New York, focused on early biotechnology and healthcare investing. Joined in2019. Her current manager biography includes boards of EpiBiologics, TRexBio, Auron, Amplifire and SunBird Bio; older company affiliations retain their own date qualifications.

TRexBio lead independent director since October 2026, following service as executive chair and board chair. Former Calistoga Pharmaceuticals CEO and former NEA partner and adviser, with experience in drug development, commercial strategy and biotechnology finance.

TRexBio vice president and head of translational medicine. Previously spent 18 years at Genentech working on disease mechanisms, biomarker discovery and clinical implementation; trained at Imperial College London, Cambridge and Harvard.

TRexBio vice president of clinical operations with experience managing early clinical studies, compliance and inspection readiness. Previously held clinical operations roles at ImmPACT Bio, PACT Pharma and PUMA Biotechnology.

TRexBio head of portfolio and alliance management. Previously led new product planning and commercial programs at Ultragenyx and held strategy, portfolio and brand-management roles at Genentech.

TRexBio chief scientific officer overseeing target discovery, validation and translation. Previously held research leadership roles at Genentech; trained in immunology at Toronto and conducted postdoctoral research at Harvard.

TRexBio chief medical officer with clinical-development experience in autoimmune and inflammatory disease. Previously worked at Biora Therapeutics, Human Immunology Biosciences and Genentech/Roche and practiced rheumatology at Stanford.

TRexBio chief financial officer. Previously CFO of Applied Molecular Transport and held finance and operating roles at Singulex, Novartis Vaccines & Diagnostics and Genentech.

TRexBio chief operating officer with experience in business development, corporate transactions, investor relations and operations. Previously led business development and investor relations at Myovant Sciences and worked in Roche Pharma Partnering; trained as an attorney.

TRexBio CEO and, since October 2026, board chair. Previously spent 36 years at Eli Lilly, including leading clinical development teams and Lilly New Ventures before retiring from Lilly in 2021.

Microbiologist with experience in research, commercialization of biotechnology and medical projects, management and board service.

Norwegian finance and biotechnology executive with an NHH MSc and UC Berkeley PhD. Own website identifies CFO; government register retains the separate legal general-manager role.

Patient navigator at myTomorrows, identified in its 2026 media coverage of caregiver participation in clinical trials.

Senior site manager at myTomorrows, identified in its 2026 media coverage of Parkinson’s disease biomarkers.

CTO of myTomorrows, leading AI adoption and technology strategy. Previously led enterprise engineering at Miro and the AWS development center in the Netherlands.

COO of myTomorrows, overseeing global operations and stakeholder engagement. Previously COO at Ade Health and a commercial leader at Bayer Pharmaceuticals.

Physician who founded myTomorrows in 2012. Previously held executive roles at Crucell and co-founded Leyden Labs.

Director of partnerships development at myTomorrows, listed in its public expert directory.

Product manager and pharmacist at myTomorrows, listed as a company expert on patient access and healthcare technology.

Head of pharma partnerships and customer success at myTomorrows, listed in its public expert directory.

Chief commercial officer of myTomorrows, leading global commercial strategy and pre-approval treatment access partnerships. Has extensive European biotechnology industry experience.

Physician and CEO of myTomorrows. Trained in medicine and economics at the University of Amsterdam, with prior oncology clinical and research experience.

Has been an Alto director since August 2025. Previously chief medical officer at Cerevel and a clinical development leader at Otsuka and Avanir. His current Alto biography also identifies a senior adviser role at Bain Capital Life Sciences and a Rapport board role.

Early-stage technology investor experienced in research spinout co-creation, investment, governance, and team building across materials, quantum chemistry, and cancer therapies.

Avego senior advisor with pharmaceutical research, clinical-development and regulatory experience. Previously led AGI Therapeutics and Athpharma and held scientific leadership roles at Horizon, Vidara and Elan.

Avego operating partner and neurologist with biotechnology company-building experience. Co-founded Vidara Therapeutics and previously helped develop epilepsy therapies at UCB and Xcel Pharmaceuticals.

Avego office manager and executive assistant who joined in 2022. Previously managed office operations at Gage Spencer and Fleming. Holds a business-management degree from the University of Tampa.

Avego assistant controller who joined in 2024. Previously worked at Interval Partners, Pura Vida Investments, One William Street Capital Management and AMG Funds.

Avego director of finance who joined in 2022. Previously worked at ZMC Advisors and Ernst & Young. A certified public accountant with accounting and biomedical-science graduate training.

Avego chief financial officer and chief compliance officer who joined in 2023. Previously held finance leadership roles at Pura Vida Investments and Arrowstreet Capital.

Avego senior associate who joined in 2024. Previously worked on healthcare investments and royalties at Marathon Asset Management and in banking at J.P. Morgan and Mizuho.

Avego vice president who joined in 2022. Previously a healthcare investment-banking associate at Nomura. Graduated from Emory with a degree in finance and accounting.

Avego principal who joined in 2024, focusing on biotechnology therapeutics. Previously worked at RA Capital, Pfizer and Memorial Sloan Kettering. Holds an immunology doctorate from Weill Cornell.

Avego principal who joined in 2021. Previously invested in healthcare at Signet Healthcare Partners and worked in healthcare investment banking at Nomura and Jefferies.

Velan Capital senior analyst who joined in 2023. Previously invested at Altium Capital and Iguana Healthcare and researched biotechnology at RBC. Holds a molecular-biology doctorate from Weill Cornell.

Avego BioScience Capital managing director who joined in 2024 after investing at Blue Owl/Cowen Healthcare Opportunities and Roivant. TRexBio director since November 2024, with resignation planned before IPO registration effectiveness.

Avego partner who joined in 2018. Previously a vice president at Leerink Partners and a healthcare investment banker at Lazard. Holds a business-administration degree from UNC Chapel Hill.

Avego partner who joined in 2021. Previously chief business officer at Iveric bio and president of Amplitude Healthcare Acquisition Corporation. Earlier experience includes NPS Pharma, Genentech and Pfizer.

Avego partner and chief investment officer of its Velan Capital strategy. Previously a healthcare analyst at Broadfin, Iguana Healthcare and Pura Vida Investments, following medical-device operating roles.

Avego managing partner who joined in 2017. Previously invested in healthcare at Metalmark Capital and worked in healthcare investment banking at Morgan Stanley.

Avego managing partner who joined in 2015. Previously held pharmaceutical logistics, specialty pharmacy and business-development roles at DDN, Centric Health Resources, West-Ward and IGI Laboratories.

Avego founder and managing partner with experience building pharmaceutical companies. Previously co-founded Vidara Therapeutics and Alaven Pharmaceutical. Also identified as Balaji Venkataraman in SEC filings.

Vascular-medicine specialist and an external healthcare expert affiliated with SHS Capital. Also listed by 415 Capital as a Senior Clinical Advisor. Both firms’ primary directories identify the same physician; these are advisory affiliations rather than firm employment.

Stellaromics director appointed February2026. Former president and chief executive of Expression Analysis and chief commercial officer of Fluidigm, with experience scaling genomics and diagnostics businesses.

Stellaromics scientific co-founder and adviser. MIT chemistry professor and Broad Institute core member researching spatial molecular biology, including STARmap and RIBOmap.

Stellaromics product development executive appointed May2026. Previously worked at Meso Scale Diagnostics, Qiagen, IsoPlexis and Quantum-Si on genomic and proteomic technologies.

Stellaromics commercial executive appointed May2026. Previously led commercial work at Abcam, Emulate, Berkeley Lights and Dovetail Genomics.

Stellaromics product management director working on genomics product commercialization and marketing.

Stellaromics human resources leader with experience advising and leading people teams.

Stellaromics computational biology and data science leader, working on machine-learning analysis pipelines and software.

Stellaromics chief technology officer with experience designing genomic sequencing platforms.

Stellaromics operations executive responsible for its operations leadership.

Genomics executive leading Stellaromics. Previously worked at Illumina and Bionano Genomics and led Cantata Bio; appointed president and chief executive in November2023.

Luca Condò is a Senior Investment Manager for CDP Venture Capital’s Evolution Fund, which backs innovative deep-technology businesses in SeriesA–B. His primary Diadem board biography describes corporate-finance work at EY and subsequent M&A and business-development positions at Recordati and Bracco Group. He holds a master’s degree in economics and business law from Bocconi University. The Diadem source and exact native manager portrait identify the existing LucaCondo person; his board affiliation is distinct from any personal investment.

Le Dr. Jean-Pierre Bizzari est membre du conseil scientifique consultatif de l'Institut National du Cancer (INCa), membre du Board International de MATWIN et Président du « New Drug Advisory Committee » de l'Organisation Européenne pour la Recherche et le Traitement du Cancer (EORTC). Précédemment, le Dr. Bizzari était en charge du développement clinique en oncologie de grands groupes pharmaceutiques au niveau mondial. Il a notamment été Vice-Président Exécutif et Directeur du développement clinique en oncologie (États-Unis, Europe, Asie et Japon) de Celgene de 2008 à 2015. Le Dr. Bizzari a ainsi participé au développement clinique de plusieurs agents anti-cancéreux tels que Taxotere®, Eloxatin®, Abraxane®, Irinotecan® mais également le Gliadel® wafer pour le traitement du glioblastome. Il a publié plus de 70 articles dans des revues scientifiques de renom et présenté plus de 160 « abstracts » lors de congrès scientifiques, en particulier sur la méthodologie des essais cliniques et les analyses de pharmacocinétique et pharmacodynamique.. Jean-Pierre Bizzari est diplômé en médecine de l'Université de Nice, spécialisé en oncologie. Il a été interne à l'Hôpital de la Pitié-Salpêtrière à Paris puis à l'Ontario Cancer Institute et au Montreal Mac Gill Cancer Center au Canada.

Mitchel Berger is published by neuro42 as Advisor. The company describes this professional background: Neurosurgeon & Director of Brain Tumor Center, UCSF. External institution titles are directory background rather than independently verified new employment appointments.

Oern R. Stuge is published by Sectoral Asset Management as Industry Partner (published affiliation). Medical-device executive with Orsco Lifesciences and earlier Medtronic leadership experience. Existing canonical OernStuge also has Carthera chair history, which is preserved.

NMD Pharma nonexecutive director and INKEF General Partner, having joined INKEF in 2019. Earlier worked in genetics research and Sanofi strategy and business development. Holds a genetics doctorate and INSEAD MBA; no personal investment implied by his board role. Inkef’s current own directory independently lists Ivan Burkov as Partner; his sourced NMD Pharma biography identifies him as General Partner. His existing genetics doctorate, INSEAD MBA, Sanofi background, Salvia affiliation and authentic issuer portrait are preserved.